Project Grant R43DA061953
Award Date
1/15/25
Completion Date
6/30/25
Dollars Obligated
$277K
Federal Agency
National Institute on Drug Abuse
Awardee
Synventa LLC (N2TUCHRTKW28)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
This $2,925,374 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop a novel reversal agent for treating overdoses from the combination of fentanyl and xylazine. The funded research will study a sequestrant compound that can simultaneously reduce levels of both fentanyl and the animal tranquilizer xylazine in the body, with the goal of restoring respiration and reversing sedation. The award...
This federal Project Grant award of $392,940 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research on the behavioral pharmacology of opioid and xylazine mixtures. The project aims to improve understanding of the interactions between opioids and xylazine, a non-opioid veterinary drug that has emerged as an adulterant contributing to the opioid crisis. The proposed studies will use well-established experimental methods...
This $251,250 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will support research by Yale University examining the cardiorespiratory impacts of the drug combination of fentanyl and xylazine. The research aims to define the dose-response relationships for respiratory depression and cardiovascular effects when these drugs are administered individually and in combination. The project will use an...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $423,708 from September 30, 2024 to September 29, 2026 to the RU School of Osteopathic Medicine (RowanSOM) to conduct research on the cardiorespiratory and subjective effects of fentanyl-xylazine drug mixtures. The key objectives are to: 1) comprehensively characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $479,731 to support the development of the "NARCOBOND" platform - a "nanosponge" containing decoy receptors for the drugs fentanyl and xylazine. The goal is to create a treatment that can safely sequester these substances in the peripheral blood, preventing their entry into the central nervous system and thereby reversing...
This $238,500 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research investigating the effects of xylazine and opioids on inhibitory transmission in the prefrontal cortex. The key objectives are to: Test whether xylazine and opioids have synergistic effects on prefrontal cortex inhibitory transmission through distinct molecular mechanisms. Determine if xylazine and opioids inhibit...
This $399,536 Project Grant was awarded by the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to design, synthesize, and test non-opioid drug candidates that can help combat the national opioid crisis, with a focus on reversing the effects of synthetic opioids like fentanyl. The key goals are to: 1) Develop and characterize chemical lead compounds and control...
This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...
The National Institutes of Health (NIH) Office of the Director awarded a Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), in the amount of $230,521.00. The award period runs from July 1, 2024 to June 30, 2026. The grant funds research to better understand the combined effects of the synthetic opioid fentanyl and the veterinary sedative xylazine on respiration, metabolism, and...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $237,750 to Temple University to conduct research on the effects of xylazine, a veterinary sedative, on methamphetamine-induced behavioral alterations in rats. The key objectives are to: (1) evaluate if xylazine enhances the acquisition and reinforcing efficacy of methamphetamine self-administration, (2) determine if xylazine exacerbates...